lentiviral mediating genetic engineered mesenchymal stem cells for releasing il-27 as a gene therapy approach for autoimmune diseases

objective: autoimmune diseases precede a complex dysregulation of the immune system. t helper17 (th17) and interleukin (il)-17 have central roles in initiation of inflammation and subsequent autoimmune diseases. il-27 significantly controls autoimmune diseases by th17 and il-17 suppression. in the present study we have created genetic engineered mesenchymal stem cells (mscs) that mediate with lentiviral vectors to release il-27 as an adequate vehicle for ex vivo gene therapy in the reduction of inflammation and autoimmune diseases. materials and methods: in this experimental study, we isolated adipose-derived mscs (ad-mscs) from lipoaspirate and subsequently characterized them by differentiation. two subunits of il-27 (p28 and ebi3) were cloned in a pcdh-513b-1 lentiviral vector. expressions of p28 and ebi3 (epstein-barr virus induced gene 3) were determined by real time polymerase chain reaction (pcr). mscs were transduced by a pcdh-cmv-p28-iresebi3- ef-copgfp-pur lentiviral vector and the bioassay of il-27 was evaluated by il-10 expression. results: cell differentiation confirmed true isolation of mscs from lipoaspirate. restriction enzyme digestion and sequencing verified successful cloning of both p28 and ebi3 in the pcdh-513b-1 lentiviral vector. real time pcr showed high expressions level of il-27 and il-10 as well as accurate activity of il-27. conclusion: the results showed transduction of functional il-27 to ad-mscs by means of a lentiviral vector. the lentiviral vector did not impact msc characteristics.